Carolina Schinke

4 weeks ago | nature.com | Eric Siegel |Carolina Schinke |Frits van Rhee |Toshali Pandey

B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR T)-cell therapy has significantly advanced the treatment of relapsed/refractory (R/R) multiple myeloma (MM) [1]. In the phase II KarMMa trial, idecabtagene vicleucel (ide-cel) achieved a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months in triple-class-exposed RRMM patients [2].

Aug 11, 2024 | nature.com | Rajshekhar Chakraborty |Aniko Szabo |Carolina Schinke |Binod Dhakal |Ghulam Rehman Mohyuddin |Martin Kaiser | +1 more

To the Editor:Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma [MM], with single-agent response rates from 57–71% [1,2,3,4,5,6].

Aug 4, 2024 | nature.com | Molly Went |Gísli H. Halldórsson |Andrea Gunnell |Philip J Law |Amit Sud |Gudmar Thorleifsson | +24 more

AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel.

Jun 28, 2024 | cco.amegroups.org | Carolina Schinke

Have a website account?Log In orRegister for exclusive website content. Home / Vol 13, No 3 (June 30, 2024) / The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells i... PDF 478 views Full Text 1 views Peer Review File 80 views COI Form 106 views

Apr 14, 2024 | onlinelibrary.wiley.com | Meera Mohan |Carolina Schinke |Ashby TC

As clinical outcomes and therapeutic options in multiple myeloma (MM) continue to improve, there is a growing interest in stratifying newly diagnosed MM patients to further tailor treatment based on disease risk.